The Latest Cardiac and Vascular News
Cardiovascular disease (CVD), a leading cause of death and disability worldwide, involves structural and functional changes in the heart Local sterile inflammation by the innate immune system results in a signalling cascade, particularly activation of NLRP3 NLRP3 activation, along with processing and release of downstream associated pro-inflammatory cytokines, IL-1β and […]
WASHINGTON–(BUSINESS WIRE)–Heart Valve Voice US, a nonprofit patient advocacy organization, is launching a new mobile app for its popular My Valve My Voice patient community. The app, now available for iOS and Android users, is among several initiatives for American Heart Month and Valve Disease Day announced today by the organization. “The […]
CHICAGO, Feb. 15, 2022 /PRNewswire/ — Cardiosense, Inc., a Chicago-based digital health company building a physiological waveform AI platform to manage cardiac disease, announced today that the U.S. Food and Drug Administration (FDA) has granted the company Breakthrough Device status for its novel algorithm to identify patients at risk of decompensated heart failure. The algorithm analyzes […]
Lipid inCode® offers greater diagnostic information for hypercholesterolemia sufferers over current NHS standard OXFORD, England, Feb. 15, 2022 (GLOBE NEWSWIRE) — GENinCode Plc (AIM: GENI), the predictive genetics company focused on the prevention of cardiovascular disease, announces the successful completion of its NHS clinical study and positive results for its Lipid inCode® test (“Lipid […]
No Effect of Omecamtiv Mecarbil On Exercise Capacity in Patients with Heart Failure with Reduced Ejection Fraction Results Will Be Presented in Late Breaking Clinical Trial Session at the American College of Cardiology 71st Annual Scientific Session & Expo NDA for Omecamtiv Mecarbil Recently Accepted for Review by FDA Based on Results of […]
MILPITAS, Calif.–(BUSINESS WIRE)–Elixir Medical, a developer of innovative, drug-eluting cardiovascular devices, today announced completion of enrollment in the BIOADAPTOR randomized controlled trial (RCT). The BIOADAPTOR RCT is evaluating the DynamX™ Coronary Bioadaptor System, the first drug-eluting coronary artery implant that adapts to vessel physiology, allowing for the restoration of normal vessel […]
TORONTO–(BUSINESS WIRE)–Conavi Medical Inc. (www.conavi.com), a leader of hybrid imaging guidance for common minimally invasive heart procedures, plans to expand the presence of its Novasight Hybrid System in the U.S. market in 2022 under the guidance of its new leadership team. Thomas Looby, chief executive officer, Conavi Medical, appointed in […]
The Bluhm Family Foundation gift further expands access to world class cardiovascular care throughout the Chicagoland area CHICAGO, Feb. 14, 2022 /PRNewswire/ — Chicago philanthropist Neil G. Bluhm and the Bluhm Family Charitable Foundation announced a $45 million gift to establish the Northwestern Medicine Bluhm Heart Hospital at Northwestern Memorial Hospital. The gift expands cardiac care capacity and addresses […]
SUNNYVALE, Calif., Feb. 14, 2022 (GLOBE NEWSWIRE) — BioCardia®, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary disease, today announces that the independent Data Safety Monitoring Board (DSMB) has completed its prespecified data review for the ongoing Phase III pivotal CardiAMP™ Cell Therapy Heart […]
The Visible Heart Laboratories utilize Stratasys 3D printing technology for student and physician education as well as medical device research EDEN PRAIRIE, Minn. & REHOVOT, Israel–(BUSINESS WIRE)–Stratasys Ltd. (NASDAQ: SSYS), a leader in polymer 3D printing solutions, today announced that it is sponsoring the University of Minnesota Visible Heart® Laboratories with a donation […]
